Published in J Hypertens on November 01, 2009
Improving Intermediate Risk Management. MARK Study (MARK) | NCT01428934
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA (2010) 5.06
Monitoring performance for blood pressure management among patients with diabetes mellitus: too much of a good thing? Arch Intern Med (2012) 2.75
The treatment of type 2 diabetes. Dtsch Arztebl Int (2014) 2.66
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68
End organ damage in hypertension. Dtsch Arztebl Int (2010) 1.51
Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ (2013) 1.43
Midlife blood pressure change and left ventricular mass and remodelling in older age in the 1946 British Birth Cohort Study. Eur Heart J (2014) 1.42
Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci (2011) 1.37
Aggressive blood pressure control increases coronary heart disease risk among diabetic patients. Diabetes Care (2013) 1.21
Blood pressure j-curve: current concepts. Curr Hypertens Rep (2012) 1.18
Optimizing blood pressure control through the use of fixed combinations. Vasc Health Risk Manag (2010) 1.17
The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. Curr Cardiovasc Risk Rep (2011) 1.17
Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int (2012) 1.15
Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol (2010) 1.13
Impact of diabetes on cardiovascular disease: an update. Int J Hypertens (2013) 1.13
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med (2012) 1.12
Retracted The significance of the j-curve in hypertension and coronary artery diseases. Korean Circ J (2011) 1.10
Comparative reproducibility of the noninvasive ultrasound methods for the assessment of vascular function. Heart Vessels (2012) 1.09
Validation of diabetes mellitus and hypertension diagnosis in computerized medical records in primary health care. BMC Med Res Methodol (2011) 1.06
Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag (2012) 1.02
A systematic review of recent clinical practice guidelines on the diagnosis, assessment and management of hypertension. PLoS One (2013) 1.01
Management of hypertension in the elderly. Nat Rev Cardiol (2012) 0.98
Vascular memory: can we broaden the concept of the metabolic memory? Cardiovasc Diabetol (2012) 0.97
Tianma gouteng yin as adjunctive treatment for essential hypertension: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med (2013) 0.95
Blood pressure gradients and cardiovascular risk factors in urban and rural populations in Abia State South Eastern Nigeria using the WHO STEPwise approach. PLoS One (2013) 0.94
Use of carvedilol in hypertension: an update. Vasc Health Risk Manag (2012) 0.92
Current perspectives on combination therapy in the management of hypertension. Integr Blood Press Control (2013) 0.92
Improving interMediAte risk management. MARK study. BMC Cardiovasc Disord (2011) 0.91
Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol (2013) 0.91
Blood pressure: the lower, the better: the con side. Diabetes Care (2011) 0.91
Prognostic significance of blood pressure response to exercise in patients with systolic heart failure. Heart Vessels (2011) 0.91
Antihypertensive treatment and blood pressure in diabetic and nondiabetic patients: the lower, the better? Diabetes Care (2011) 0.90
2013 Korean Society of Hypertension guidelines for the management of hypertension. Part II-treatments of hypertension. Clin Hypertens (2015) 0.90
Hypertension in the elderly. World J Cardiol (2012) 0.89
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study. Cardiovasc Diabetol (2012) 0.89
Current challenges in the clinical management of hypertension. Nat Rev Cardiol (2011) 0.89
Global left ventricular load in asymptomatic aortic stenosis: covariates and prognostic implication (the SEAS trial). Cardiovasc Ultrasound (2012) 0.89
Trends in hypertension prevalence, awareness, treatment and control in an adult type 2 diabetes Spanish population between 2003 and 2009. PLoS One (2014) 0.89
Olmesartan/amlodipine: a review of its use in the management of hypertension. Vasc Health Risk Manag (2011) 0.89
[Cardiovascular comorbidity and its risk factors in rheumatoid arthritis]. Z Rheumatol (2011) 0.89
The Nurse-Based Age Independent Intervention to Limit Evolution of Disease After Acute Coronary Syndrome (NAILED ACS) Risk Factor Trial: Protocol for a Randomized Controlled Trial. JMIR Res Protoc (2014) 0.88
What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment? Cardiovasc Diabetol (2012) 0.88
Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol (2010) 0.87
Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension. Vasc Health Risk Manag (2013) 0.87
Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care (2011) 0.86
Treatment of risk factors to prevent stroke. Neurotherapeutics (2011) 0.86
Blood pressure lowering in patients with diabetes--one level might not fit all. Nat Rev Cardiol (2010) 0.86
Prevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy. Eur J Prev Cardiol (2012) 0.85
Occult chronic kidney disease among persons with hypertension in the United States: data from the National Health and Nutrition Surveys 1988-1994 and 1999-2002. J Hypertens (2013) 0.84
Prevalence and determinants of controlled hypertension in a German population cohort. BMC Public Health (2013) 0.84
Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring. Drugs R D (2014) 0.84
Diabetes, hypertension, and outcome studies: overview 2010. Diabetes Care (2011) 0.84
Connecting cerebral white matter lesions and hypertensive target organ damage. J Aging Res (2011) 0.84
Antihypertensive Treatment in the Elderly and Very Elderly: Always "the Lower, the Better?". Int J Hypertens (2011) 0.84
Primary stroke prevention and hypertension treatment: which is the first-line strategy? Neurol Int (2011) 0.84
Plasma neuropeptide Y (NPY) and alpha-melanocyte stimulating hormone (a-MSH) levels in patients with or without hypertension and/or obesity: a pilot study. Am J Cardiovasc Dis (2011) 0.83
Pharmacotherapy for childhood obesity: present and future prospects. Int J Obes (Lond) (2012) 0.83
Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy. J Hypertens (2011) 0.83
Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension. Clin Res Cardiol (2012) 0.83
Diabetic nephropathy - Epidemiology in Asia and the current state of treatment. Indian J Nephrol (2011) 0.83
Neck circumference and lowest oxygen saturation are independently associated with high coexistence of hypertension in obstructive sleep apnea. Yonsei Med J (2014) 0.82
Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. Health Qual Life Outcomes (2015) 0.82
Cardiovascular magnetic resonance in systemic hypertension. J Cardiovasc Magn Reson (2012) 0.82
Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Vasc Health Risk Manag (2011) 0.82
Hypertension in elderly patients: recommended systolic targets are not evidence based. Can Fam Physician (2013) 0.82
South African hypertension practice guideline 2014. Cardiovasc J Afr (2015) 0.82
The older patient with hypertension: care and cure. Ther Adv Chronic Dis (2012) 0.81
Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials. Drug Des Devel Ther (2015) 0.81
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc Health Risk Manag (2012) 0.81
Balancing influence between actors in healthcare decision making. BMC Health Serv Res (2011) 0.81
Current status of aggressive blood pressure control. World J Cardiol (2011) 0.81
The impact of blood pressure variability on subclinical ventricular, renal and vascular dysfunction, in patients with hypertension and diabetes. Maedica (Buchar) (2013) 0.81
Hypertension in autosomal-dominant polycystic kidney disease (ADPKD). Clin Kidney J (2013) 0.80
25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. Clin Res Cardiol (2012) 0.80
Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag (2011) 0.80
Preventing the progression of prehypertension to hypertension: role of antihypertensives. Curr Hypertens Rep (2015) 0.80
Suitability of antiplatelet therapy in hypertensive patients. J Hum Hypertens (2014) 0.80
Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes. CMAJ (2013) 0.79
Physician perception of blood pressure control and treatment behavior in high-risk hypertensive patients: a cross-sectional study. PLoS One (2011) 0.79
Out-of-office blood pressure: from measurement to control. Integr Blood Press Control (2012) 0.79
Management of blood pressure in patients with type 2 diabetes mellitus: a nationwide survey in korean. Diabetes Metab J (2011) 0.79
Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension. Drugs R D (2013) 0.79
RAS blockade for every diabetic patient: pro and con. Diabetes Care (2011) 0.79
Echocardiographic markers of left ventricular dysfunction among men with uncontrolled hypertension and stage 3 chronic kidney disease. Med Sci Monit (2013) 0.79
A cardiovascular educational intervention for primary care professionals in Spain: positive impact in a quasi-experimental study. Br J Gen Pract (2015) 0.79
The impact of blood pressure on kidney function in the elderly: a cross-sectional study. Kidney Blood Press Res (2014) 0.79
Personalized vascular medicine: individualizing drug therapy. Vasc Med (2011) 0.79
Predictors of poor blood pressure control assessed by 24 hour monitoring in patients with type B acute aortic dissection. Vasc Health Risk Manag (2012) 0.79
Target blood pressure in diabetes patients with hypertension--what is the accumulated evidence in 2011? J Zhejiang Univ Sci B (2011) 0.78
Association of E/E' and NT-proBNP with renal function in patients with essential hypertension. PLoS One (2013) 0.78
Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension. Integr Blood Press Control (2011) 0.78
Long-Term Tolerability and Efficacy of Single-Pill Combinations of Telmisartan 40-80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5-10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies. Curr Ther Res Clin Exp (2012) 0.78
Moderate versus intensive treatment of hypertension using amlodipine/valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial/ethnic subgroups. J Am Soc Hypertens (2011) 0.78
Treating blood pressure to prevent strokes: The age factor. World J Cardiol (2013) 0.78
Urinary protein excretion is associated with left ventricular hypertrophy in treatment-naïve hypertensive patients in an african hospital setting. Cardiorenal Med (2013) 0.78
Hypertension: Cardiac hypertrophy as a target of antihypertensive therapy. Nat Rev Cardiol (2010) 0.78
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet (2008) 35.06
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet (2008) 16.92
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (2010) 14.40
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (2004) 11.13
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43